• Target micro, small and medium-sized enterprises;
• Operate on commercial lines and markets rates through equity investments;
• Foster cooperation with local parties as well as commercial investors such as banks, insurance companies, investment funds, and other financial institutions;
• Adhere to international standards of environmental and social requirements and comply with the international laws to ensure transparency in the financial operations.

Sun Ventures strives to achieve returns which are appropriate to the opportunities and risks of the emerging markets.



Diversification

Sun Ventures is committed to building a broad portfolio that addresses important unmet medical needs and advances cutting-edge technologies that will define the life science industry over the next decade, as well as a portfolio that balances the risks inherent in an early-stage fund. With this in mind, our life science portfolio is diversified by both sector and stage as defined below:

Sectors

• Drug development companies discovering and developing drugs focused on specific therapeutic areas such as anti-infectives, diabetes, metabolic diseases, and oncology.
  
• Product discovery platforms developing innovative technologies to create superior molecules and improve the discovery process by reducing cost, time, and risk.
  
• Medical technologies focusing on areas such as drug delivery, diagnostics, imaging agents, materials science, and medical devices.

Stages
Innovative platforms with the potential to improve the life science industry via the introduction of novel disruptive technologies.
Shorter-term products with near-term opportunities intended to improve the portfolio's overall risk-return profile.
Spin-outs created directly out of pharmaceutical or other large life science companies after the products or technologies have been incubated and validated.



Keys to success

Venture capital is an interpersonal medium. As such, both network and teamwork are crucial. By drawing on the knowledge and resources of our friends and colleagues in the larger scientific and venture capital communities, we can better identify and grow leading-edge life science technologies. And by melding our own venture capital, scientific, operational, and financial competencies, the Sun Ventures team is able to realise greater value for our shareholders and portfolio companies.

Venture capital is also in the details. To that end, Sun Ventures relies on portfolio diversification, hands-on company building, and capital efficiency to build significant shareholder value.

In addition to our own hands-on steering of company growth, Sun Ventures builds value in portfolio companies through strategic company mergers and acquisitions, asset-bolstering, advanced product and technology acquisitions, and milestone-based staged financing.